Clear opinion differences between Sanofi vs LG over ‘Zemiglo’
The outline of the lawsuit over ‘Zemiglo,’ an antidiabetic developed by LG Life Sciences, became visible.
The first defense for the damage suit filed by the previous seller of Zemiglo, Sanofi-Aventis Korea, against the original developer, LG Life Sciences, and the current seller, Daewoong Phar...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
